Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.
A new drug combination shows promise for treating hormone-receptor-positive breast cancer that has resisted prior treatments.
The aim of PANKU-Breast01 was to compare the efficacy and safety of iza-bren versus chemotherapy in patients with pretreated HR+/HER2- breast cancer. Baili-Bio (Chengdu) Pharmaceutical, CAMS Innovation Fund for Medical Sciences, Noncommunicable Chronic Diseases-National Science and Technology Major Project, National High Level Hospital Clinical Research Funding, and the National Natural Science Foundation of China.
What the study was
- Study design
- Randomized controlled trial
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Lancet
Why it surfaced
Randomized controlled trial; human evidence; PubMed abstract reviewed; conservative rubric score 10/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.